Dexamethasone News and Research

RSS

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Exuberant activation of immune cells in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

9 Oct 2020

Liquid gel in COVID patients' lungs could be the key to new effective therapies

In some patients who died with severe COVID-19 and respiratory failure, a jelly was formed in the lungs. Researchers have now established what the active agent in the jelly is and thanks to that, this new discovery can now be the key to new effective therapies.

6 Oct 2020

Study fails to establish independent risk factors for SARS-COV-2 infection in HIV patients

As the COVID-19 pandemic continues to spread worldwide, a new study published in the International Journal of Infectious Diseases in September 2020 reports that people with HIV infection are not at greater risk of COVID-19 compared to the general population.

5 Oct 2020

New commitments from governments and organizations support a unified approach to end pandemic

New commitments from governments, international organizations and the private sector support unified approach to end pandemic, backing a response of unprecedented scale, scope and speed - through the Access to COVID-19 Tools Accelerator - as pandemic claims more than 1 million lives

1 Oct 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

University of Minnesota receives funding to initiate research on diabetes drug as a COVID-19 treatment

University of Minnesota Medical School researchers received funding from the Parsemus Foundation to initiate research on the widely-used diabetes medication, metformin, available globally as an inexpensive generic drug for prevention and treatment for COVID-19.

25 Sep 2020

Biomarker predicts disease severity in COVID-19 patients

Airway cell analyses showing an activated immune axis could pinpoint the COVID-19 patients who will most benefit from targeted therapies.

17 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Conditions linked to obesity leave the lungs of obese patients more susceptible to COVID-19

Conditions related to obesity, including inflammation and leaky gut, leave the lungs of obese patients more susceptible to COVID-19 and may explain why they are more likely to die from the disease, UTSW scientists say in a new article published online in eLife.

16 Sep 2020

New book gives overview of viruses and how they emerge to cause pandemics

Since the novel coronavirus SARS-Cov-2 emerged late last year, it has been virtually impossible to consume any news without encountering stories about the virus and how it spreads, potential treatments, and the development of new vaccines.

11 Sep 2020

Examining the role of endocrine system and hormones in COVID-19 infection

The evidence for hormone involvement in COVID-19 infection and treatment will be evaluated and discussed by endocrine experts in a dedicated COVID-19 session at e-ECE 2020.

3 Sep 2020

Corticosteroids can be lifesaving for critically ill COVID-19 patients

Now, a prospective meta-analysis of 7 randomized trials published in the journal JAMA showed that the widely available steroid drugs could help seriously ill patients survive COVID-19.

3 Sep 2020

Treating critically ill COVID-19 patients with steroid improves chances of recovery

A new international study published today [02 September] has shown that treating critically ill patients with COVID-19 with the steroid hydrocortisone improves their chances of recovery.

2 Sep 2020

Inhaled steroid ciclesonide suppresses SARS-CoV-2 replication in vitro

A new paper by researchers at Japan’s National Institute of Infectious Diseases and published on the preprint server bioRxiv in August 2020 reports the in vitro suppression of coronavirus (CoV) replication by an inhaled corticosteroid (ICS) ciclesonide.

26 Aug 2020

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

25 Aug 2020

Historic study that evidenced the benefits of anti-COVID steroids could have saved lives

A study from early in the global coronavirus pandemic that evidenced the benefits of using steroids to combat COVID-19 in severely ill patients could have saved lives, according to the University of Huddersfield researchers involved.

18 Aug 2020

Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes' was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

12 Aug 2020

Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.

5 Aug 2020

Dexamethasone should be a standard drug in severe COVID-19

Many scientists have explored the use of new as well as already approved drugs for this condition, and one of the very few promising leads is dexamethasone. Dexamethasone is a corticosteroid, which has been reported in some earlier studies to reduce mortality in these patients by 18% and 36% in COVID-19 patients who are on oxygen and ventilators, respectively.

3 Aug 2020